ALEC | Alector, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.68 - 6.05
52 Week Range	3.66 - 8.90
Beta	0.48
Implied Volatility	175.41%
IV Rank	56.01%
Day's Volume	480,997
Average Volume	569,443
Shares Outstanding	97,321,100
Market Cap	552,783,848
Sector	Healthcare
Industry	Biotechnology
IPO Date	2019-02-07

Valuation
Profitability
Growth
Health
P/E Ratio	-3.14
Forward P/E Ratio	N/A
EPS	-1.81
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	245
Country	USA
Website	ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

ALEC's peers: ACET, ADCT, PASG, BDTX, TCRR, HARP, RVMD, BCEL, STOK, FIXX, GLUE, CABA, LRMR, ALZN, CRNX, DARE, DTIL, ETON, GMAB, GOSS, HALO, MRKR, MRVI, NKTX, QSI, SLDB, TSHA, ZYME

*Chart delayed

Analyzing fundamentals for ALEC we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see ALEC Fundamentals page.

Watching at ALEC technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on ALEC Technicals page.